Danausgt

DanausGT Biotech is an innovative cell and gene therapy company, currently with offices in China and in the EU, which aims to provide a disease modifying and curative treatment to children suffering of rare devastating diseases. Together, we have a revolutionary gene editing CRISPR 3.0 platform technology that has been demonstrated to precisely insert large corrected gene fragments into the genome, and as a consequence target the vast population of pediatric patients suffering of a disease. Its features are precise, efficient, safe and clinically applicable. This is a cutting-edge technology allowing gene correction with almost the no risk of off-target related adverse events. The platform technology can be extended to many disease areas, such as rare diseases, cancer and so on. With this technology, DanausGT is taking a leading position in the cell and gene therapy field globally. We have thriving rare disease pipeline, such as our lead candidate for Pyruvate Kinase Deficiency, which obtained orphan drug designation (ODD) in both Europe and US. At DanausGT, we listen to the voice of our patients and empathize with their pain. Therefore, our sole focus is to provide these patients with a curable medicine. We stand strong behind our logo of ‘making medicine for one child’. Even if there were only one child, we will develop the necessary medicine to cure this child. We believe this is our moral obligation and that we are doing the right thing, and embark on this worthy challenge with your support.